In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to beat. But no companies had taken a daunting head-to-head challenge—until ...

Linda Hoffman-Pugh, a former housekeeper for JonBenét Ramsey's family, has died at the age of 82. Hoffman-Pugh was working for the family when JonBenét was tragically murdered at just 6 years old on ...

Patsy Kensit will return to Emmerdale after two decades to reprise her role as Sadie King. The actress played the villainous character on the ITV soap for a two-year stint between 2004 and 2006. She ...

Emmerdale has confirmed the return of Patsy Kensit as Sadie King. It was recently reported that the star, who appeared on EastEnders a few years ago, would be back as the villainous character after 20 ...

You don’t mess with the classics. In a chaotic world that ceaselessly hurls distractions at us through the digital rectangular devices in our pockets, it’s often the slow, frill-less, anachronistic ...

“These results highlight zanubrutinib monotherapy as an effective treatment option for all patients with treatment-naive CLL/[small lymphocytic leukemia], including patients who might otherwise be ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue their conversation on communicating ...

Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

CLL17 finds fixed-duration venetoclax regimens match continuous ibrutinib at 3 years, boosting confidence in personalized frontline CLL choices. Results from the phase 3 CLL17 trial (NCT04608318) are ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...